Paper

0

Document

Submit new version

Download

Flag content

0

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Molecular Biology

Show More

Authors

Meletios Dimopoulos,Andrew Spencer

Michael Attal,H. Prince,Jean Harousseau,Anna Dmoszyńska,Jesús Miguel,Andrzej Hellmann,Thierry Façon,Robin Foà,Alessandro Gozzetti,Zvenyslava Masliak,Marta Olesnyckyj,Zhinuan Yu,John Patin,Jerome Zeldis,Robert Knight

+15 authors

Journal

New England Journal of Medicine

Published

Nov 21, 2007

DOI

10.1056/nejmoa070594

Show more

Save

Tip

Document

Submit new version

Download

Flag content

0

Tip

Save

Document

Submit new version

Download

Flag content

Abstract

Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma.

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.